Table II.
Comparison of body mass index, prostate specific antigen and quality of life (EQ-5D-5L) scores within and between patients in the placebo and mefenamic acid groups.
| Time | |||
|---|---|---|---|
| Parameters per group | Baseline (Mean ± standard deviation) | 6 months (Mean ± standard deviation) | bP-value |
| Prostate-specific antigen, ng/ml | |||
| Placebo | 10.15±7.17 ng/ml | 17.18±13.04 ng/ml | 0.012 |
| Mefenamic acid | 7.00±7.80 ng/ml | 5.38±7.80 ng/ml | 0.018 |
| aP-value | 0.383 | 0.024 | |
| Body Mass Index | |||
| Placebo | 27.70±1.87 | 27.70±3.63 | 0.898 |
| Mefenamic acid | 30.33±4.79 | 32.50±5.75 | 0.064 |
| aP-value | 0.112 | 0.038 | |
| EQ-5D-5L score | |||
| Placebo | 6.66±2.05 | 5.38±0.75 | 0.108 |
| Mefenamic acid | 7.33±2.00 | 5.66±0.66 | 0.015 |
| aP-value | 0.513 | 0.422 | |
a
Mefenamic acid groups vs. balanced placebo.
b
Baseline vs. 6 months.